Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 13/20 | 0.41 |
| ▸ | FPR1 | P21462 | 2/20 | 0.41 |
| ▸ | FPR2 | P25090 | 2/20 | 0.41 |
| ▸ | MC1R | Q01726 | 3/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17799746 | 0.87 | MC1R (0.45) | HCRTR1FPR1FPR2MC1RHCRTR2 | |
| SCHEMBL17799752 | 0.86 | MC1R (0.42) | HCRTR1FPR1FPR2MC1RTAS1R3 | |
| SCHEMBL17799730 | 0.85 | HCRTR1 (0.53) | HCRTR1MC1RHCRTR2 | |
| SCHEMBL17799632 | 0.84 | EGFR (0.46) | HCRTR1FPR1FPR2MC1RTAS1R3 | |
| SCHEMBL17799720 | 0.82 | GRM5 (0.45) | HCRTR1MC1RHCRTR2 | |
| SCHEMBL17799638 | 0.82 | HCRTR1 (0.54) | HCRTR1MC1RHCRTR2 | |
| SCHEMBL17799674 | 0.81 | GRM5 (0.39) | HCRTR1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL17799751 | 0.81 | MC1R (0.39) | HCRTR1FPR1FPR2MC1RHPGD | |
| SCHEMBL17799646 | 0.81 | MC1R (0.45) | HCRTR1FPR1FPR2MC1R | |
| SCHEMBL19767311 | 0.81 | HCRTR1 (0.43) | HCRTR1MC1RHCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50724-E1 | 4-membered ring carboxamides used as nematicides | SYNGENTA CROP PROTECTION AG (CH) | 2026-01-06 | — | — | US | disclosed |
| EP-3019476-B1 | 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2018-01-17 | — | — | EP | disclosed |
| US-9867371-B2 | 4-membered ring carboxamides used as nematicides | SYNGENTA PARTICIPATIONS AG (CH) | 2018-01-16 | — | — | US | disclosed |
| US-20160157485-A1 | 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160157485-A1 | 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES | TUBA3C, DDT, CYCS | HCRTR1 57/4885FPR1 605/4885FPR2 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.